Printer Friendly
The Free Library
23,403,340 articles and books


Progressive Alternative Medicine Solution Undergoes Clinical Trials and Holds Promise of Benefiting Millions of Americans with Hepatitis C.

PHOENIX -- An estimated five million Americans have been infected with hepatitis C virus (HCV) according to a study published at the Liver Meeting by the American Association for the Study of Liver Diseases (AASLD) in November 2005. Chronic hepatitis C is associated with significant morbidity (liver cirrhosis and hepatocellular carcinoma) and mortality. Current treatment is based on interferon and ribavirin. However, treatment options are limited for patients who are not candidates for interferon-based therapy, particularly for those who suffer from HCV genotype 1 infection.

Sho-saiko-to (SST), a standardized herbal formula, is under a clinical phase II trial by a leading New York Cancer Research Institute to determine its effect on hepatitis C patients. The research group has reported the preliminary results of 15 patients at the 2nd Society of Integrative Oncology Conference in San Diego on November 10, 2005. This study is titled "Sho-saiko-to for Patients with Chronic Hepatitis C Who Are Intolerant to or Have Contraindication to Interferon-Based Therapy: A Phase II Study." SST is know to have anti-fibrotic effect by inhibition of lipid peroxidation in hepatocytes and stellate cells in animal studies. It has also been shown to reduce aminotransferase levels and the incidence of hepatocellular carcinoma in hepatitis and liver cirrhosis patients.

According to the design of the clinical trial, 31 patients will receive SST daily for 52 weeks. Fifteen patients have completed the treatment and the preliminary results have been reported. No serious adverse events have been attributed to SST among any patients who enrolled in the trial. Among the 15 patients who completed the study, reductions in alanine aminotransferase (ALT) were observed in 11 patients and aspartate aminotransferase (AST) in 10 patients. In 10 patients, the liver biopsy showed 20% improvement on histological assessment of the liver. This is consistent with the findings by the Japanese researchers for its anti-inflammatory effect. More interestingly, the majority of the patients whom participated in the clinical trial were genotype 1 infection.

In Japan, over 75% of physicians use at least some of the traditional herbal formulas. Over 1.5 million Japanese patients with hepatitis have been treated with Sho-saiko-to. SST is available in capsules through HepCare Inc. (www.HepZone.com), a Phoenix-based company that has licensed the marketing right of SST from Honso Pharmaceutical Co. Ltd., the Nagoya-based Japanese manufacturer of the standardized herbal formula.

For more information about SST, please visit www.HepZone.com, call 800-996-4SST (778) or e-mail info@hepzone.com.

HepZone(R) is a registered trademark of HepCare Inc., 4602 E. Elwood St., Suite 6, Phoenix, AZ 85040.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:May 23, 2006
Words:423
Previous Article:Intellon Working to Include HomePlug Powerline Enabled Products in Home Networks Managed by Windows Rally; Solution Will Make Intellon-Enabled...
Next Article:Summer Snacks Keep Kids Happy and Healthy; Mealsmatter.org Offers Quick, Kid-Friendly Ideas.
Topics:



Related Articles
City announces fund investment.
GILEAD SUBMITS MAA TO EMEA FOR ADEFOVIR DIPIVOXIL 10 MG.
MEDICURE GETS FDA/TPD APPROVALS FOR MC-1 PHASE II TRIAL.
US ONCOLOGY CENTER OFFERS AUSTCANCER'S REVISYS SUPPLEMENTS.
Hepatitis coinfection: two major studies published.
Current challenges in hepatitis C.
The hepatitis C drug development pipeline.
Intracerebral hemorrhage: the least treatable form of stroke.
AVI BioPharma Provides Update on Hepatitis C Virus Clinical Trial Status; Data from the Phase I/II Accepted for Oral Platform Presentation at ICAR.
Roche Driving PROGRESS in Treatment of Hepatitis C Patients with New PEGASYS(R) Trial.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters